NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference, scheduled for June 17-18, 2026. President and CEO Dave Rosa will attend the conference in Las Vegas, Nevada, where he is set to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, at 12:00 p.m. Pacific Time.
The presentation, which will take place in TRACK 6 - Raphael 3, will provide commercialization updates and anticipated milestones for the OneRF platform, which is designed for treatment of the brain, pain, and advanced drug delivery. Additionally, Mr. Rosa participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference, which can be viewed here.
NeuroOne markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The Planet MicroCap Conference is a key event for small-cap companies to connect with institutional investors. NeuroOne's participation underscores its efforts to raise awareness of its technology and upcoming milestones. For more information on the conference or to schedule a meeting with management, interested parties can contact their conference representative or reach out via email to NMTC@mzgroup.us or call Chris Tyson at (949) 491-8235.
NeuroOne's stock trades on the Nasdaq under the ticker NMTC. The company's technology has the potential to transform surgical diagnosis and treatment for neurological disorders, and its presentation at the conference may provide insights into its commercial progress and future direction. Investors and industry observers will be watching for updates on the OneRF platform and other pipeline developments.
